While a useful diagnostic and prognostic aid, PSA levels cannot be considered without supporting clinical evidence; for example, 2% of PCa patients harbor an aggressive form of prostate cancer (Gleason score ≥ 7) despite PSA levels < 4 ng/mL [24], and false positives are also common. This evidence concerns the gene KLK3 and prostate carcinoma.